The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

The association between mutations of key driver genes and colorectal cancer (CRC)
metastasis has been investigated by many studies. However, the results of these studies …

The colon is derived from the embryological midgut and hindgut separately, with the right
colon and left colon having different features with regards to both anatomical and …

Background The frequency rates of mutations such as KRAS, NRAS, BRAF, and PIK3CA in
colorectal cancer (CRC) differ among populations. The aim of this study was to assess …

Background The aim of this study was to clarify clinicopathological features, frequencies of
molecular biomarkers, and prognoses in Japanese colorectal cancer patients and compare …

Abstract Background CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype
in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor …

Current prognostic indicators are ineffective for identifying advanced-stage colorectal cancer
(CRC) patients with high risk of recurrence after surgical resection. We investigated the …

Family history is an important factor in determining hereditary cancer risk for many cancer
types. The emergence of next-generation sequencing (NGS) has expedited the discovery of …

KRAS and BRAF mutation rates in colorectal cancer (CRC) reported from various mono-
ethnic studies vary amongst different ethnic groups. However, these differences in mutation …

Background BRAF and KRAS mutations are well-established biomarkers in anti-EGFR
therapy. However, the prognostic significance of these mutations is still being examined. We …